Published in PLoS One on March 12, 2008
The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the Heart and Soul Study. Ann Intern Med (2010) 4.89
Fetuin-A acts as an endogenous ligand of TLR4 to promote lipid-induced insulin resistance. Nat Med (2012) 2.60
Plasma fetuin-A levels and the risk of type 2 diabetes. Diabetes (2008) 2.41
Dissociation between fatty liver and insulin resistance in humans carrying a variant of the patatin-like phospholipase 3 gene. Diabetes (2009) 2.36
Mechanisms linking obesity, chronic kidney disease, and fatty liver disease: the roles of fetuin-A, adiponectin, and AMPK. J Am Soc Nephrol (2010) 1.75
Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease. Nutrients (2013) 1.73
The metabolically benign and malignant fatty liver. Diabetes (2011) 1.39
The role of hepatokines in metabolism. Nat Rev Endocrinol (2013) 1.21
Association of fetuin-a with incident diabetes mellitus in community-living older adults: the cardiovascular health study. Circulation (2012) 1.18
Insulin resistance in patients with chronic kidney disease. J Biomed Biotechnol (2012) 1.15
Fetuin-A, type 2 diabetes, and risk of cardiovascular disease in older adults: the cardiovascular health study. Diabetes Care (2012) 1.06
The association of fetuin-A with cardiovascular disease mortality in older community-dwelling adults: the Rancho Bernardo study. J Am Coll Cardiol (2012) 1.06
Serum fetuin-A associates with type 2 diabetes and insulin resistance in Chinese adults. PLoS One (2011) 1.02
Insulin promotes glycogen storage and cell proliferation in primary human astrocytes. PLoS One (2011) 1.02
Association between carotid diameter and the advanced glycation end product N-epsilon-carboxymethyllysine (CML). Cardiovasc Diabetol (2009) 1.02
The I148M PNPLA3 polymorphism influences serum adiponectin in patients with fatty liver and healthy controls. BMC Gastroenterol (2012) 1.00
Fetuin-A and change in body composition in older persons. J Clin Endocrinol Metab (2009) 0.97
Circulating fetuin-A and free fatty acids interact to predict insulin resistance in humans. Nat Med (2013) 0.96
Hepatokines as a Link between Obesity and Cardiovascular Diseases. Diabetes Metab J (2015) 0.94
Urinary fetuin-A is a novel marker for diabetic nephropathy in type 2 diabetes identified by lectin microarray. PLoS One (2013) 0.93
Increased selenoprotein p levels in subjects with visceral obesity and nonalcoholic Fatty liver disease. Diabetes Metab J (2013) 0.89
Non-alcoholic steatohepatitis and hepatocellular carcinoma: implications for lycopene intervention. Nutrients (2013) 0.89
Impact of the adipokine adiponectin and the hepatokine fetuin-A on the development of type 2 diabetes: prospective cohort- and cross-sectional phenotyping studies. PLoS One (2014) 0.89
Plasma fetuin-A concentrations in young and older high- and low-active men. Metabolism (2010) 0.88
Associations of fetuin-A levels with vascular disease in type 2 diabetes patients with early diabetic nephropathy. Cardiovasc Diabetol (2010) 0.88
Genetic ablation of cGMP-dependent protein kinase type I causes liver inflammation and fasting hyperglycemia. Diabetes (2011) 0.88
Fetuin-A levels in obesity: differences in relation to metabolic syndrome and correlation with clinical and laboratory variables. Arch Med Sci (2012) 0.85
Fetuin-A: a novel link between obesity and related complications. Int J Obes (Lond) (2014) 0.84
Exercise-induced lowering of fetuin-A may increase hepatic insulin sensitivity. Med Sci Sports Exerc (2014) 0.84
Potential role of Helicobacter pylori infection in nonalcoholic fatty liver disease. World J Gastroenterol (2013) 0.84
Association between higher serum fetuin-A concentrations and abnormal albuminuria in middle-aged and elderly chinese with normal glucose tolerance. Diabetes Care (2010) 0.82
Searching for cellular partners of hantaviral nonstructural protein NSs: Y2H screening of mouse cDNA library and analysis of cellular interactome. PLoS One (2012) 0.81
Serum fetuin A and chemerin levels correlate with hepatic steatosis and regional adiposity in maintenance hemodialysis patients. PLoS One (2012) 0.80
AMP-activated Protein Kinase (AMPK): Does This Master Regulator of Cellular Energy State Distinguish Insulin Sensitive from Insulin Resistant Obesity? Curr Obes Rep (2014) 0.80
Enforced expression of protein kinase C in skeletal muscle causes physical inactivity, fatty liver and insulin resistance in the brain. J Cell Mol Med (2010) 0.80
Exendin-4 Inhibits the Expression of SEPP1 and Fetuin-A via Improvement of Palmitic Acid-Induced Endoplasmic Reticulum Stress by AMPK. Endocrinol Metab (Seoul) (2014) 0.79
Circulating levels of adiponectin, leptin, fetuin-A and retinol-binding protein in patients with tuberculosis: markers of metabolism and inflammation. PLoS One (2012) 0.79
Can serum fetuin-A be regarded as an inflammatory marker among patients with familial Mediterranean fever? Dig Dis Sci (2013) 0.78
Fetuin-A, a new vascular biomarker of cognitive decline in older adults. Clin Endocrinol (Oxf) (2014) 0.77
Implication of hepatokines in metabolic disorders and cardiovascular diseases. BBA Clin (2016) 0.77
Serum fetuin-A levels related with microalbuminuria in diet-induced obese rats. Biomed Res Int (2012) 0.77
The relationship of fetuin-A and lactoferrin with bone mass in elderly women. Osteoporos Int (2010) 0.77
Association between alcohol consumption and plasma fetuin-A and its contribution to incident type 2 diabetes in women. Diabetologia (2013) 0.76
Matrix γ-carboxyglutamate protein and Fetuin-A, in wet type age-related macular degeneration. Int J Ophthalmol (2015) 0.76
Associations of Erythrocyte Fatty Acids in the De Novo Lipogenesis Pathway with Proxies of Liver Fat Accumulation in the EPIC-Potsdam Study. PLoS One (2015) 0.76
Proinflammatory and lipid biomarkers mediate metabolically healthy obesity: A proteomics study. Obesity (Silver Spring) (2016) 0.76
The effect of regular colchicine treatment on biomarkers related with vascular injury in newly diagnosed patients with familial Mediterranean fever. Inflammation (2012) 0.76
The impact of insulin resistance on the kidney and vasculature. Nat Rev Nephrol (2016) 0.75
Relationship between serum levels of fetuin-A with apo-A1, apo-B100, body composition and insulin resistance in patients with type 2 diabetes. Med J Islam Repub Iran (2014) 0.75
Fetuin-A and Risk of Diabetes Independent of Liver Fat Content: The Multi-Ethnic Study of Atherosclerosis. Am J Epidemiol (2016) 0.75
Fetuin-A, glycemic status, and risk of cardiovascular disease: The Multi-Ethnic Study of Atherosclerosis. Atherosclerosis (2016) 0.75
Metabolic Adaptation in Obesity and Type II Diabetes: Myokines, Adipokines and Hepatokines. Int J Mol Sci (2016) 0.75
Interaction between plasma fetuin-A and free fatty acids predicts changes in insulin sensitivity in response to long-term exercise. Physiol Rep (2017) 0.75
The relationship of circulating fetuin-a with liver histology and biomarkers of systemic inflammation in nondiabetic subjects with nonalcoholic fatty liver disease. Saudi J Gastroenterol (2015) 0.75
Association of atherosclerotic peripheral arterial disease with adiponectin genes SNP+45 and SNP+276: a case-control study. Biomed Res Int (2013) 0.75
Effects of Exercise Training and Weight Loss on Plasma Fetuin-A Levels and Insulin Sensitivity in Overweight Older Men. J Diabetes Res (2017) 0.75
Association of fetuin-A to adiponectin ratio with metabolic syndrome: a cross-sectional study. Endocrine (2017) 0.75
Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia (1985) 109.13
Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest (2003) 41.22
Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest (2003) 32.01
Adipose tissue as an endocrine organ. J Clin Endocrinol Metab (2004) 11.94
Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab (2001) 9.53
Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest (2006) 9.49
Plasma adiponectin levels and risk of myocardial infarction in men. JAMA (2004) 7.46
The serum protein alpha 2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. J Clin Invest (2003) 3.71
Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet (2003) 3.70
Quantitative trait loci on chromosomes 3 and 17 influence phenotypes of the metabolic syndrome. Proc Natl Acad Sci U S A (2000) 3.44
Adipose tissue-derived factors: impact on health and disease. Endocr Rev (2006) 3.16
Adiponectin multimeric complexes and the metabolic syndrome trait cluster. Diabetes (2006) 3.14
Alpha2-Heremans-Schmid glycoprotein/fetuin-A is associated with insulin resistance and fat accumulation in the liver in humans. Diabetes Care (2006) 2.99
Measurement of the high-molecular weight form of adiponectin in plasma is useful for the prediction of insulin resistance and metabolic syndrome. Diabetes Care (2006) 2.77
Plasma adiponectin concentrations predict insulin sensitivity of both glucose and lipid metabolism. Diabetes (2003) 2.71
Regulation of adiponectin by adipose tissue-derived cytokines: in vivo and in vitro investigations in humans. Am J Physiol Endocrinol Metab (2003) 2.71
Adiponectin in youth: relationship to visceral adiposity, insulin sensitivity, and beta-cell function. Diabetes Care (2004) 2.60
Mechanisms of Disease: hepatic steatosis in type 2 diabetes--pathogenesis and clinical relevance. Nat Clin Pract Endocrinol Metab (2006) 2.31
Association between human fetuin-A and the metabolic syndrome: data from the Heart and Soul Study. Circulation (2006) 2.27
Oligomerization state-dependent activation of NF-kappa B signaling pathway by adipocyte complement-related protein of 30 kDa (Acrp30). J Biol Chem (2002) 2.20
Adiponectin, risk of coronary heart disease and correlations with cardiovascular risk markers. Eur Heart J (2005) 2.16
Improved insulin sensitivity and resistance to weight gain in mice null for the Ahsg gene. Diabetes (2002) 1.99
Characterization of a natural inhibitor of the insulin receptor tyrosine kinase: cDNA cloning, purification, and anti-mitogenic activity. Cell (1989) 1.96
Adiponectin and future coronary heart disease events among men with type 2 diabetes. Diabetes (2005) 1.87
Hormonal regulation of adiponectin gene expression in 3T3-L1 adipocytes. Biochem Biophys Res Commun (2002) 1.86
Adiponectin gene expression and secretion is inhibited by interleukin-6 in 3T3-L1 adipocytes. Biochem Biophys Res Commun (2003) 1.82
Plasma adiponectin levels and sonographic phenotypes of subclinical carotid artery atherosclerosis: data from the SAPHIR Study. Stroke (2005) 1.73
Tissue distribution and activity testing suggest a similar but not identical function of fetuin-B and fetuin-A. Biochem J (2003) 1.72
Serum high molecular weight complex of adiponectin correlates better with glucose tolerance than total serum adiponectin in Indo-Asian males. Diabetologia (2005) 1.69
Association of serum fetuin-A with insulin resistance in type 2 diabetic and nondiabetic subjects. Diabetes Care (2006) 1.57
Serum alpha 2-HS-glycoprotein is an inhibitor of the human insulin receptor at the tyrosine kinase level. Mol Endocrinol (1993) 1.50
The nucleotide and partial amino acid sequences of rat fetuin. Identity with the natural tyrosine kinase inhibitor of the rat insulin receptor. Eur J Biochem (1992) 1.49
Linkage of plasma adiponectin levels to 3q27 explained by association with variation in the APM1 gene. Diabetes (2005) 1.35
Alpha2-HSG, a specific inhibitor of insulin receptor autophosphorylation, interacts with the insulin receptor. Mol Cell Endocrinol (2000) 1.23
Bovine fetuin is an inhibitor of insulin receptor tyrosine kinase. Life Sci (1997) 1.19
Adipose conversion of 3T3-L1 cells in a serum-free culture system depends on epidermal growth factor, insulin-like growth factor I, corticosterone, and cyclic AMP. J Biol Chem (1990) 1.14
Influences of ionomycin, dibutyryl-cycloAMP and tumour necrosis factor-alpha on intracellular amount and secretion of apM1 in differentiating primary human preadipocytes. Horm Metab Res (2001) 1.11
Increased expression of TNF-alpha, IL-6, and IL-8 in HALS: implications for reduced adiponectin expression and plasma levels. Am J Physiol Endocrinol Metab (2003) 1.11
Dyslipidemia in visceral obesity: mechanisms, implications, and therapy. Am J Cardiovasc Drugs (2004) 1.11
High local concentrations and effects on differentiation implicate interleukin-6 as a paracrine regulator. Obes Res (2004) 1.09
The complete cDNA and amino acid sequence of bovine fetuin. Its homology with alpha 2HS glycoprotein and relation to other members of the cystatin superfamily. J Biol Chem (1990) 1.08
A synonymous coding polymorphism in the alpha2-Heremans-schmid glycoprotein gene is associated with type 2 diabetes in French Caucasians. Diabetes (2005) 1.06
Evidence for a local renin angiotensin system in primary cultured human preadipocytes. Int J Obes Relat Metab Disord (1999) 1.05
Differential expression of insulin receptor tyrosine kinase inhibitor (fetuin) gene in a model of diet-induced obesity. Life Sci (1998) 0.99
Association of serum fetuin-A with carotid arterial stiffness. Clin Endocrinol (Oxf) (2007) 0.98
Adiponectin: protection of the endothelium. Curr Diab Rep (2005) 0.98
Hepatic steatosis and vascular disease. Eur Rev Med Pharmacol Sci (2005) 0.95
Gene transcription in hepatocytes during the acute phase of a systemic inflammation: from transcription factors to target genes. Inflamm Res (2001) 0.95
Systemic inhibition of spontaneous calcification by the serum protein alpha 2-HS glycoprotein/fetuin. Z Kardiol (2001) 0.94
alpha2-Heremans-Schmid glycoprotein gene polymorphisms are associated with adipocyte insulin action. Diabetologia (2004) 0.90
Regulation of NCAM by growth factors in serum-free myotube cultures. J Neurosci Res (1993) 0.79
Identification and characterization of metabolically benign obesity in humans. Arch Intern Med (2008) 5.74
T-helper-1-cell cytokines drive cancer into senescence. Nature (2013) 4.47
An accurate risk score based on anthropometric, dietary, and lifestyle factors to predict the development of type 2 diabetes. Diabetes Care (2007) 4.14
Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. Ann Intern Med (2003) 4.11
Physical activity attenuates the influence of FTO variants on obesity risk: a meta-analysis of 218,166 adults and 19,268 children. PLoS Med (2011) 3.94
Alpha2-Heremans-Schmid glycoprotein/fetuin-A is associated with insulin resistance and fat accumulation in the liver in humans. Diabetes Care (2006) 2.99
High alanine aminotransferase is associated with decreased hepatic insulin sensitivity and predicts the development of type 2 diabetes. Diabetes (2002) 2.98
Causes and metabolic consequences of Fatty liver. Endocr Rev (2008) 2.84
Plasma adiponectin concentrations predict insulin sensitivity of both glucose and lipid metabolism. Diabetes (2003) 2.71
Identification of serum metabolites associated with risk of type 2 diabetes using a targeted metabolomic approach. Diabetes (2012) 2.62
Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. J Hepatol (2009) 2.43
Plasma fetuin-A levels and the risk of type 2 diabetes. Diabetes (2008) 2.41
Dissociation between fatty liver and insulin resistance in humans carrying a variant of the patatin-like phospholipase 3 gene. Diabetes (2009) 2.36
Changes of the plasma metabolome during an oral glucose tolerance test: is there more than glucose to look at? Am J Physiol Endocrinol Metab (2008) 2.32
Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. Diabetes Care (2005) 2.30
Polymorphisms within novel risk loci for type 2 diabetes determine beta-cell function. PLoS One (2007) 2.16
Palmitate, but not unsaturated fatty acids, induces the expression of interleukin-6 in human myotubes through proteasome-dependent activation of nuclear factor-kappaB. J Biol Chem (2004) 2.12
Interaction effect between common polymorphisms in PPARgamma2 (Pro12Ala) and insulin receptor substrate 1 (Gly972Arg) on insulin sensitivity. J Mol Med (Berl) (2001) 2.11
Plasma fetuin-a levels and the risk of myocardial infarction and ischemic stroke. Circulation (2008) 2.08
Hepatic lipid composition and stearoyl-coenzyme A desaturase 1 mRNA expression can be estimated from plasma VLDL fatty acid ratios. Clin Chem (2009) 2.02
Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele. Cancer Res (2002) 1.95
Impact of age on the relationships of brown adipose tissue with sex and adiposity in humans. Diabetes (2010) 1.90
Standardized assessment of whole body adipose tissue topography by MRI. J Magn Reson Imaging (2005) 1.85
A new wound-based severity score for diabetic foot ulcers: A prospective analysis of 1,000 patients. Diabetes Care (2006) 1.78
Processing of food pictures: influence of hunger, gender and calorie content. Brain Res (2010) 1.77
Identification of proliferative and mature β-cells in the islets of Langerhans. Nature (2016) 1.71
Follow-up whole-body assessment of adipose tissue compartments during a lifestyle intervention in a large cohort at increased risk for type 2 diabetes. Radiology (2010) 1.71
Relationship of serum adiponectin and leptin concentrations with body fat distribution in humans. Obes Res (2003) 1.65
High circulating retinol-binding protein 4 is associated with elevated liver fat but not with total, subcutaneous, visceral, or intramyocellular fat in humans. Diabetes Care (2007) 1.64
Palmitate-induced interleukin-6 expression in human coronary artery endothelial cells. Diabetes (2004) 1.63
Subjective feeling of appetite modulates brain activity: an fMRI study. Neuroimage (2006) 1.59
Impact of variation in the FTO gene on whole body fat distribution, ectopic fat, and weight loss. Obesity (Silver Spring) (2008) 1.59
Intramyocellular lipids: anthropometric determinants and relationships with maximal aerobic capacity and insulin sensitivity. J Clin Endocrinol Metab (2003) 1.58
Breast-feeding and maternal risk of type 2 diabetes: a prospective study and meta-analysis. Diabetologia (2014) 1.58
Association of the T-G polymorphism in adiponectin (exon 2) with obesity and insulin sensitivity: interaction with family history of type 2 diabetes. Diabetes (2002) 1.55
The cerebrocortical response to hyperinsulinemia is reduced in overweight humans: a magnetoencephalographic study. Proc Natl Acad Sci U S A (2006) 1.51
Association of type 2 diabetes candidate polymorphisms in KCNQ1 with incretin and insulin secretion. Diabetes (2009) 1.50
Muscle-derived angiopoietin-like protein 4 is induced by fatty acids via peroxisome proliferator-activated receptor (PPAR)-delta and is of metabolic relevance in humans. Diabetes (2008) 1.48
The obese brain: association of body mass index and insulin sensitivity with resting state network functional connectivity. Hum Brain Mapp (2011) 1.46
Use of multiple metabolic and genetic markers to improve the prediction of type 2 diabetes: the EPIC-Potsdam Study. Diabetes Care (2009) 1.46
The cancer-associated FGFR4-G388R polymorphism enhances pancreatic insulin secretion and modifies the risk of diabetes. Cell Metab (2013) 1.45
Relationships of circulating sex hormone-binding globulin with metabolic traits in humans. Diabetes (2010) 1.43
Novel meta-analysis-derived type 2 diabetes risk loci do not determine prediabetic phenotypes. PLoS One (2008) 1.41
[A case of acute and intense thoracic pain during a dental treatment]. Dtsch Med Wochenschr (2010) 1.40